- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.08. | Freenome, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 18.08. | Freenome stock initiated at Buy by TD Cowen on liquid biopsy tech | 1 | Investing.com | ||
| 17.08. | BTIG startet Freenome mit Kaufempfehlung und sieht fast 50 % Kurspotenzial | 1 | Investing.com Deutsch | ||
| 17.08. | BTIG initiates Freenome stock with buy rating on cancer test potential | 1 | Investing.com | ||
| 17.08. | Jefferies initiates Freenome stock with buy rating on cancer screening potential | 2 | Investing.com | ||
| 17.08. | Jefferies startet Freenome mit Kaufempfehlung: Hohes Potenzial bei Krebs-Screening | 1 | Investing.com Deutsch | ||
| 14.08. | Freenome GAAP EPS of -$2.59 | 1 | Seeking Alpha | ||
| FREENOME Aktie jetzt für 0€ handeln | |||||
| 12.08. | Freenome, Inc.: FDA Grants Breakthrough Device Designation to Freenome's Blood-Based SimpleScreen Lung Cancer Screening Test | 218 | GlobeNewswire (Europe) | BRISBANE, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the U.S. Food and... ► Artikel lesen | |
| 24.07. | Freenome, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.07. | NSE - Freenome, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | 2 | SEC Filings | ||
| 20.07. | Freenome Holdings, Inc. - 15-15D, Suspension of duty to report | 2 | SEC Filings | ||
| 20.07. | Freenome, Inc. - 8-A12B, Registration of securities | 1 | SEC Filings | ||
| 20.07. | Krebsdiagnostik-Spezialist Freenome geht via SPAC an die Nasdaq | - | Investing.com Deutsch | ||
| 20.07. | Freenome, Inc.: Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection | 400 | GlobeNewswire (Europe) | - Freenome common stock expected to begin trading on the Nasdaq Capital Market under the ticker symbol "FRNM" on July 21, 2026 - - Gross proceeds to Freenome totaled more than $300 million through... ► Artikel lesen | |
| 13.07. | Freenome colorectal cancer test data improve on earlier results | 1 | BioPharma Dive | ||
| 11.06. | Freenome Holdings, Inc. - S-4/A, Registration of securities, business combinations | - | SEC Filings | ||
| 01.06. | Freenome Holdings, Inc. - S-4/A, Registration of securities, business combinations | 2 | SEC Filings | ||
| 28.04. | Freenome Holdings, Inc. - S-4, Registration of securities, business combinations | - | SEC Filings | ||
| 05.12.25 | Freenome Holdings, Inc.: Freenome and Perceptive Capital Solutions Corp Announce Business Combination Agreement to Create a Publicly Listed Company Transforming Blood-Based Multi-Cancer Detection through an AI/ML-Enabled Multiomics Platform | 735 | PR Newswire | - Leading institutional investors commit $240 million through private investment in public equity (PIPE) led by Perceptive Advisors and RA Capital -
- Freenome... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 17,550 | 0,00 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| TANGO THERAPEUTICS | 23,780 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,870 | 0,00 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen | ||
| VERA THERAPEUTICS | 35,090 | +0,11 % | Vera Therapeutics: Erfolgreicher Start für Nierenmedikament TRUTAKNA | ||
| QIAGEN | 36,525 | -0,25 % | BERENBERG stuft QIAGEN NV auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Qiagen mit einem Kursziel von 40 Euro auf "Hold" belassen. Der Medizintechnik- und Life-Science-Sektor bleibe fundamental attraktiv, wie die... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,230 | +0,11 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 44,450 | +0,11 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 79,31 | 0,00 % | Jefferies erhöht Kursziel für Tarsus Pharmaceuticals nach Prognoseanhebung | ||
| ARCUTIS BIOTHERAPEUTICS | 23,880 | -0,02 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| COGENT BIOSCIENCES | 33,410 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ERASCA | 15,890 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| ARCUS BIOSCIENCES | 24,570 | 0,00 % | Arcus Biosciences: Casdatifan-Strategie auf der Cantor Global Healthcare Conference im Fokus | ||
| IMMUNOVANT | 37,330 | -0,08 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 10,545 | 0,00 % | Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors | Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness NEEDHAM, Mass., Sept. 10, 2026... ► Artikel lesen | |
| MODERNA | 124,98 | +0,68 % | Moderna-Aktie bei 144 US$: Nächstes Hoch in Sicht? | Die Moderna-Aktie konnte gestern um +5,38% zulegen, nachdem der Kurs zuvor rund -34% korrigiert hatte. Damit zeigt sich nach dem deutlichen Rücksetzer eine erste Gegenbewegung. Nun stellt sich die entscheidende... ► Artikel lesen |
FREENOME INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,010 (+0,07 %) liegt der Kurs bei 14,380 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FREENOME INC finden Sie auf Wallstreet Online.